su011248

Refractory Malignant Solid Neoplasm

Rabin Medical CenterPhase 2Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 47/ 100
Competitive Position: 81/ 100

Competitive context

76 Active assets in the Refractory Malignant Solid Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Irinotecan M.D. Anderson Cancer Center	Phase 2	BB
Cediranib National Cancer Institute (NCI)	Phase 2	BB
Nivolumab CatalYm GmbH	Phase 2	BB
Olaparib Fundación de investigación HM	Phase 2	BB
AZD1775 National Cancer Institute (NCI)	Phase 2	B

View all 50 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant

BBB

Indicative ·

75 / 100

Pancreatic Neuroendocrine TumorDormant

BB

Indicative ·

69 / 100

Renal Cell CarcinomaDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.